• Cereno Scientific reported positive topline results from a Phase I pharmacokinetic bridging study of HDAC inhibitor CS014.
• Results have been presented as topline data; fuller findings are slated for publication in 2027.
• Study supported the planned regulatory strategy to move CS014 directly into Phase IIb in PH-ILD, pending FDA review.
• Safety profile was consistent with prior Phase I experience, with mild adverse events and no serious events.
• IND submission is planned for Q4 2026; Phase IIb start is targeted for Q3 2027, subject to regulatory clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on September 25, 2026, and is solely responsible for the information contained therein.